Isopropyl-p-tolylsulfid | 77572-67-9

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: Isopropyl-p-tolylsulfid
• 英文别名: isopropenyl 4-methylphenyl sulfide；Isopropenyl p-tolyl sulfide；1-methyl-4-prop-1-en-2-ylsulfanylbenzene
• CAS: 77572-67-9
• 化学式: C₁₀H₁₂S
• 分子量: 164.271
• InChiKey: ZDFZJMWJBQZGHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Isopropyl-p-tolylsulfid 、 3-[(E)-3-(methoxycarbonyl)-propenoyl]-oxazolidin-2-one 以14%的产率得到
  参考文献：
  名称：

  Narasaka Koichi, Hayashi Yujiro, Shimadzu Hideshi, Niihata Shigeo, J. Amer. Chem. Soc., 114 (1992) N 23, S 8869-8885

  摘要：

  DOI：
• 作为产物：
  描述：

  propane-2,2-diylbis(p-tolylsulfane) 在 二叔丁基过氧化物 作用下， 以 氯苯 为溶剂， 生成 Isopropyl-p-tolylsulfid
  参考文献：
  名称：

  Homolytic rearrangement with the migration of an alkylthio or arylthio group

  摘要：

  DOI：

  10.1007/bf00843995

文献信息

• Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：US10709790B2

  公开（公告）日：2020-07-14

  The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.

  本发明涉及式 I 或式 II 的化合物或其药学上可接受的酯、酰胺、溶液或盐，或此类酯或酰胺的盐或此类酯酰胺或盐的溶液：式 I 式 II 式 I 的化合物可与治疗性化合物或其片段共价键合，以提供式 II 的化合物，从而延长治疗性化合物的半衰期。本发明还涉及所公开化合物的药物组合物及其在疾病诊断或治疗中的用途。
• Asymmetric [2 + 2] cycloaddition reaction catalyzed by a chiral titanium reagent
  作者：Koichi Narasaka、Yujiro Hayashi、Hideshi Shimadzu、Shigeo Niihata

  DOI：10.1021/ja00049a020

  日期：1992.11

  In the presence of certain Lewis acids, alkenes containing an alkylthio group (for example, ketene dithioacetals, alkenyl sulfides, alkynyl sulfides, and allenyl sulfides) react with electron deficient olefins to give the corresponding cyclobutane, cyclobutene, or methylene cyclobutane derivatives. By employing a chiral titanium catalyst generated in situ from dichlorodiisopropoxytitanium and a tartrate-derived chiral diol, the [2 + 2] cycloaddition reaction proceeds with high enantioselectivity.
• Synthesis of 1-(1-Arylsulfanylalkyl)indoles and 2,2-Bis[1-(1-arylsulfanylalkyl)indol-3-yl]propanes by Acid-Catalyzed Reactions of Indoles with Aryl Vinyl Sulfides
  作者：Kazuhiro Kobayashi、Yuu Shirai、Shuhei Fukamachi、Hisatoshi Konishi

  DOI：10.3987/com-09-11867

  日期：——

  We report a facile synthesis of 1-(1-arylsulfanylalkyl)indoles and 2,2-bis[1-(1-arylsulfanylalkyl)indol-3-yl]propanes under mild conditions. Thus, treatment of 3-substituted indoles with aryl vinyl sulfides in dichloromethane at room temperature in the presence of a catalytic amount of (+/-)-camphor-10-sulfonic acid yields the former indole derivatives in moderate to fair yields. 3-Nonsubstituted indoles can be transformed into the latter indole derivatives in satisfactory yields on treatment with excess aryl vinyl sulfides in the presence of a catalytic amount of the acid under similar conditions.
• CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES
  申请人：Centro De Ingenieria Genetica Y Biotecnologia

  公开号：EP2258356B1

  公开（公告）日：2017-09-27
• CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF LONG-ACTING THERAPEUTICS
  申请人：THE UNITED STATES OF AMERICA ,AS REPRESENTED BY TH E SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVIC

  公开号：US20190201537A1

  公开（公告）日：2019-07-04

  The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.